Se Jin Cho1, Sun Mi Baek2, Dong Gyu Na3,4, Kang Dae Lee5, Young Kee Shong6, Jung Hwan Baek7. 1. Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Gyeonggi, Republic of Korea. 2. Department of Radiology, Haeundae Sharing and Happiness Hospital, 502, Jwadongsunhwan-ro, Haeundae-gu, Busan, 48101, Republic of Korea. 3. Department of Radiology, GangNeung Asan Hospital, Gangneung, Republic of Korea. 4. Department of Radiology, Human Medical Imaging and Intervention Center, Seoul, Republic of Korea. 5. Department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan, 49267, Republic of Korea. 6. Division of Endocrinology & Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 7. Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 86 Asanbyeongwon-Gil, Songpa-Gu, Seoul, 05505, Republic of Korea. radbeak@naver.com.
Abstract
OBJECTIVES: Confidence in long-term treatment results of thermal ablation for papillary thyroid microcarcinoma (PTMC) is required in comparison with active surveillance. The objective of this meta-analysis is to report 5-year follow-up results of thermal ablation for PTMC. METHODS: Ovid MEDLINE and EMBASE databases were searched through May 30, 2020, for studies reporting outcomes in patients with PTMC treated with thermal ablation and followed up for at least 5 years. Data were extracted and methodological quality was assessed independently by two radiologists according to the PRISMA guidelines. RESULTS: Three studies, involving 207 patients with 219 PTMCs, met the inclusion criteria through database searches. None of these patients experienced local tumor recurrence, lymph node metastasis, or distant metastasis or underwent delayed surgery during a mean pooled 67.8-month follow-up. Five new tumors appeared in the remaining thyroid gland of four patients, with four of these tumors successfully treated by repeat thermal ablation. The pooled mean major complication rate was 1.2%, with no patient experiencing life-threatening or delayed complications. CONCLUSIONS: Thermal ablation is an excellent local tumor control method in patients with low-risk PTMC, with low major complication rates at 5 years. KEY POINTS: • No local tumor recurrence, lymph node metastasis, or distant metastasis was noted by thermal ablation during follow-up of 5 years and none underwent delayed surgery. • The pooled mean major complication rate was 1.2%.
OBJECTIVES: Confidence in long-term treatment results of thermal ablation for papillary thyroid microcarcinoma (PTMC) is required in comparison with active surveillance. The objective of this meta-analysis is to report 5-year follow-up results of thermal ablation for PTMC. METHODS: Ovid MEDLINE and EMBASE databases were searched through May 30, 2020, for studies reporting outcomes in patients with PTMC treated with thermal ablation and followed up for at least 5 years. Data were extracted and methodological quality was assessed independently by two radiologists according to the PRISMA guidelines. RESULTS: Three studies, involving 207 patients with 219 PTMCs, met the inclusion criteria through database searches. None of these patients experienced local tumor recurrence, lymph node metastasis, or distant metastasis or underwent delayed surgery during a mean pooled 67.8-month follow-up. Five new tumors appeared in the remaining thyroid gland of four patients, with four of these tumors successfully treated by repeat thermal ablation. The pooled mean major complication rate was 1.2%, with no patient experiencing life-threatening or delayed complications. CONCLUSIONS: Thermal ablation is an excellent local tumor control method in patients with low-risk PTMC, with low major complication rates at 5 years. KEY POINTS: • No local tumor recurrence, lymph node metastasis, or distant metastasis was noted by thermal ablation during follow-up of 5 years and none underwent delayed surgery. • The pooled mean major complication rate was 1.2%.
Authors: Se Jin Cho; Chong Hyun Suh; Jung Hwan Baek; Sae Rom Chung; Young Jun Choi; Ki-Wook Chung; Young Kee Shong; Jeong Hyun Lee Journal: Thyroid Date: 2019-09-27 Impact factor: 6.568
Authors: Salvatore Vaccarella; Silvia Franceschi; Freddie Bray; Christopher P Wild; Martyn Plummer; Luigino Dal Maso Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: So Yeong Jeong; Jung Hwan Baek; Young Jun Choi; Sae Rom Chung; Tae Yon Sung; Won Gu Kim; Tae Yong Kim; Jeong Hyun Lee Journal: Int J Hyperthermia Date: 2018-01-24 Impact factor: 3.914
Authors: Linda M Youngwirth; Mohamed A Adam; Randall P Scheri; Sanziana A Roman; Julie A Sosa Journal: Ann Surg Oncol Date: 2015-09-28 Impact factor: 5.344
Authors: Ralph P Tufano; Gary Clayman; Keith S Heller; William B Inabnet; Electron Kebebew; Ashok Shaha; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2015-01 Impact factor: 6.568